Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
BACKGROUND: Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess the efficacy and safety of alirocumab, evolocumab and bococizumab in patients with atherosclerotic cardiovascul...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Via Medica
2022-07-01
|
| Col·lecció: | Cardiology Journal |
| Matèries: | |
| Accés en línia: | https://journals.viamedica.pl/cardiology_journal/article/view/75703 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|